keyword
MENU ▼
Read by QxMD icon Read
search

hymenoptera venom allergy

keyword
https://www.readbyqxmd.com/read/29331065/component-resolved-diagnostics-to-direct-in-venom-immunotherapy-important-steps-towards-precision-medicine
#1
Simon Blank, Maria Beatrice Bilò, Markus Ollert
Stings of Hymenoptera can induce IgE-mediated systemic and even fatal allergic reactions. Venom-specific immunotherapy (VIT) is the only disease-modifying and curative treatment of venom allergy. However, choosing the correct venom for VIT represents a necessary prerequisite for efficient protection against further anaphylactic sting reactions after VIT. In the past, therapeutic decisions based on the measurement of specific IgE (sIgE) levels to whole venom extracts were not always straightforward, especially when the patient was not able to identify the culprit insect...
January 13, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29258788/anaphylactic-reactions-after-discontinuation-of-hymenoptera-venom-immunotherapy-a-clonal-mast-cell-disorder-should-be-suspected
#2
Patrizia Bonadonna, Roberta Zanotti, Mauro Pagani, Massimiliano Bonifacio, Luigi Scaffidi, Elisa Olivieri, Maurizio Franchini, Federico Reccardini, Maria Teresa Costantino, Chiara Roncallo, Marina Mauro, Elisa Boni, Fabio Lodi Rizzini, Maria Beatrice Bilò, Anna Rosaria Marcarelli, Giovanni Passalacqua
BACKGROUND: Up to 75% of patients with severe anaphylactic reactions after Hymenoptera sting are at risk of further severe reactions if re-stung. Venom immunotherapy (VIT) is highly effective in protecting individuals with ascertained Hymenoptera venom allergy (HVA) and previous severe reactions. After a 3- to 5-year VIT course, most patients remain protected after VIT discontinuation. Otherwise, a lifelong treatment should be considered in high-risk patients (eg, in mastocytosis). Several case reports evidenced that patients with mastocytosis and HVA, although protected during VIT, can re-experience severe and sometimes fatal reactions after VIT discontinuation...
December 16, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29202591/venom-immunotherapy-in-patients-with-allergic-reactions-to-insect-stings
#3
Cristoforo Incorvaia, Marina Mauro, Bruna L Gritti, Eleni Makri, Erminia Ridolo
Allergy to Hymenoptera (Apis mellifera, Vespula species, Polistes species, Vespa crabro) venom can be safely and effectively treated by venom immunotherapy (VIT), which in the 40 years since its introduction has been able to prevent reactions to stings, and to treatment as well, though systemic reactions, occasionally severe, are possible. Areas covered: We reviewed the recent literature on VIT by searching in PubMed for the terms "venom immunotherapy" and "Hymenoptera venom immunotherapy" to highlight the current status of VIT and the likely development in the coming years...
December 5, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29171032/immunological-differences-between-insect-venom-allergic-patients-with-and-without-immunotherapy-and-asymptomatically-sensitized-subjects
#4
Lisa Arzt, Danijela Bokanovic, Christoph Schrautzer, Karin Laipold, Christian Möbs, Wolfgang Pfützner, Sereina Annik Herzog, Jutta Vollmann, Norbert Reider, Barbara Bohle, Werner Aberer, Gunter Sturm
BACKGROUND: Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings. METHODS: We included 77 asymptomatically-sensitized subjects, 85 allergic-patients with acute systemic sting reactions, and 61 allergic-patients currently treated with VIT...
November 23, 2017: Allergy
https://www.readbyqxmd.com/read/29156294/phospholipase-a1-based-cross-reactivity-among-venoms-of-clinically-relevant-hymenoptera-from-neotropical-and-temperate-regions
#5
Amilcar Perez-Riverol, Luís Gustavo Romani Fernandes, Alexis Musacchio Lasa, José Roberto Aparecido Dos Santos-Pinto, Débora Moitinho Abram, Gabriel Hideki Izuka Moraes, Frederic Jabs, Michaela Miehe, Henning Seismman, Mario Sergio Palma, Ricardo de Lima Zollner, Edzard Spillner, Márcia Regina Brochetto-Braga
Molecular cross-reactivity caused by allergen homology or cross-reactive carbohydrate determinants (CCDs) is a major challenge for diagnosis and immunotherapy of insect venom allergy. Venom phospholipases A1 (PLA1s) are classical, mostly non-glycosylated wasp and ant allergens that provide diagnostic benefit for differentiation of genuine sensitizations from cross-reactivity. As CCD-free molecules, venom PLA1s are not causative for CCD-based cross-reactivity. Little is known however about the protein-based cross-reactivity of PLA1 within vespid species...
November 17, 2017: Molecular Immunology
https://www.readbyqxmd.com/read/29130986/skin-test-reactivity-to-hymenoptera-venom-after-venom-immunotherapy-correlates-inversely-with-the-igg-ige-ratio
#6
Ieva Saulite, Wolfram Hoetzenecker, Emmanuella Guenova, Peter Schmid-Grendelmeier, Martin Glatz
BACKGROUND: Skin test reactivity to hymenoptera venom and venom-specific IgE are important for diagnosing venom allergy and deciding on the appropriate allergen for venom immunotherapy (VIT). Longitudinal data on skin test reactivity during VIT and their correlation with venom-specific immunoglobulin (Ig)E and IgG are scarce. METHODS: We retrospectively analyzed shifts in skin test reactivity and serum levels of venom-specific IgE and IgG in patients allergic to hymenoptera venom before the initiation of VIT with ultrarush therapy and after ≥3 years of VIT...
2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/29106324/safety-of-specific-immunotherapy-using-an-ultra-rush-induction-regimen-in-bee-and-wasp-allergy
#7
Andrzej Bożek, Krzysztof Kołodziejczyk
BACKGROUND: Specific allergen immunotherapy to Hymenoptera venom (VIT) is a basic treatment for patients allergic to Hymenoptera venom. The aim of the study was to evaluate the safety of an ultra-rush regimen compared with the rush and conventional protocols. MATERIALS AND METHODS: In 31 patients with an allergy to bee venom and 82 with an allergy to wasp venom, the allergic adverse reactions during VIT were monitored. Patients were selected based on the criteria established by EAACI (European Academy of Allergy and Clinical Immunology) recommendations...
November 6, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28950273/venom-immunotherapy-in-high-risk-patients-the-advantage-of-the-rush-build-up-protocol
#8
Yossi Rosman, Ronit Confino-Cohen, Arnon Goldberg
BACKGROUND: Venom immunotherapy (VIT) is considered to be the gold standard treatment for patients with hymenoptera venom allergy. This treatment induces systemic reactions (SR) in a significant number of patients. OBJECTIVE: To evaluate the outcome of VIT in patients with known risk factors for VIT-induced SR and to compare rush VIT (RVIT) and conventional VIT (CVIT). METHODS: All of the patients who received VIT and had at least one of the following risk factors were included: current cardiovascular disease, uncontrolled asthma, high basal serum tryptase, current treatment with β-blockers or angiotensin-converting enzyme inhibitors, and age >70 or <5 years...
2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28837089/heterologous-expression-purification-and-immunoreactivity-of-the-antigen-5-from-polybia-paulista-wasp-venom
#9
Murilo Luiz Bazon, Amilcar Perez-Riverol, José Roberto Aparecido Dos Santos-Pinto, Luis Gustavo Romani Fernandes, Alexis Musacchio Lasa, Débora Laís Justo-Jacomini, Mario Sergio Palma, Ricardo de Lima Zollner, Márcia Regina Brochetto-Braga
Polybia paulista (Hymenoptera: Vespidae) is responsible for a high number of sting accidents and anaphylaxis events in Southeast Brazil, Argentina and Paraguay. The specific detection of allergy to the venom of this wasp is often hampered by the lack of recombinant allergens currently available for molecular diagnosis. Antigen 5 (~23 kDa) from P. paulista venom (Poly p 5) is a highly abundant and glycosylated allergenic protein that could be used for development of component-resolved diagnosis (CRD). Here, we describe the cloning and heterologous expression of the antigen 5 (rPoly p 5) from P...
August 24, 2017: Toxins
https://www.readbyqxmd.com/read/28796123/hymenoptera-induced-anaphylaxis-is-it-a-mast-cell-driven-hematological-disorder
#10
Knut Brockow, Cem Akin
PURPOSE OF REVIEW: Hymenoptera-induced allergy (HVA) is a common cause of anaphylaxis and may be fatal. It is associated with systemic mastocytosis in about 7% of adult patients. Systemic mastocytosis is a proliferative disorder of hematopoietic mast cell progenitors. There is recent data on the association between systemic mastocytosis and HVA. RECENT FINDINGS: Hymenoptera venoms are the most common immunoglobulin E-mediated elicitors of anaphylaxis in patients with mastocytosis...
October 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28796121/climate-changes-and-hymenoptera-venom-allergy-are-there-some-connections
#11
Stefano Turillazzi, Francesco Turillazzi
PURPOSE OF REVIEW: This review aims to update the world status of the main allergenic stinging Hymenoptera. RECENT FINDINGS: In this review, we consider the problems that social Hymenoptera (bees, wasps and ants) could represent in the nearest future for human health in different parts of the world. SUMMARY: Distribution and consistency of allergenic species including venomous insects are interested by accelerated dynamics caused by climate changes and globalization...
October 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28759475/component-resolved-diagnostics-for-hymenoptera-venom-allergy
#12
Thilo Jakob, Ulrich Müller, Arthur Helbling, Edzard Spillner
PURPOSE OF REVIEW: Component-resolved diagnostics makes use of defined allergen molecules to analyse IgE-mediated sensitizations at a molecular level. Here, we review recent studies on the use of component-resolved diagnostics in the field of Hymenoptera venom allergy (HVA) and discuss its benefits and limitations. RECENT FINDINGS: Component resolution in HVA has moved from single molecules to panels of allergens. Detection of specific immunoglobulin E (sIgE) to marker and cross-reactive venom allergens has been reported to facilitate the discrimination between primary sensitization and cross-reactivity and thus, to provide a better rationale for prescribing venom immunotherapy (VIT), particularly in patients sensitized to both honeybee and vespid venom...
October 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28748641/eaaci-guidelines-on-allergen-immunotherapy-hymenoptera-venom-allergy
#13
Gunter J Sturm, Eva-Maria Varga, Graham Roberts, Holger Mosbech, M Beatrice Bilò, Cezmi A Akdis, Darío Antolín-Amérigo, Ewa Cichocka-Jarosz, Radoslaw Gawlik, Thilo Jakob, Mitja Kosnik, Joanna Lange, Ervin Mingomataj, Dimitris I Mitsias, Markus Ollert, Joanna N G Oude Elberink, Oliver Pfaar, Constantinos Pitsios, Valerio Pravettoni, Franziska Ruëff, Betül Ayşe Sin, Ioana Agache, Elizabeth Angier, Stefania Arasi, Moises A Calderón, Montserrat Fernandez-Rivas, Susanne Halken, Marek Jutel, Susanne Lau, Giovanni B Pajno, Ronald van Ree, Dermot Ryan, Otto Spranger, Roy Gerth van Wijk, Sangeeta Dhami, Hadar Zaman, Aziz Sheikh, Antonella Muraro
Hymenoptera venom allergy is a potentially life-threatening allergic reaction following a honeybee, vespid or ant sting. Systemic allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or moderate-to-severe with a risk of life-threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H1 -antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s)...
July 27, 2017: Allergy
https://www.readbyqxmd.com/read/28739022/component-resolved-diagnosis-in-hymenoptera-allergy
#14
REVIEW
D Antolín-Amérigo, B Ruiz-León, E Boni, T Alfaya-Arias, M Álvarez-Mon, J Barbarroja-Escudero, D González-de-Olano, C Moreno-Aguilar, M Rodríguez-Rodríguez, M J Sánchez-González, L Sánchez-Morillas, A Vega-Castro
Component-resolved diagnosis based on the use of well-defined, properly characterised and purified natural and recombinant allergens constitutes a new approach in the diagnosis of venom allergy. Prospective readers may benefit from an up-to-date review on the allergens. The best characterised venom is that of Apis mellifera, whose main allergens are phospholipase A2 (Api m1), hyaluronidase (Api m2) and melittin (Api m4). Additionally, in recent years, new allergens of Vespula vulgaris have been identified and include phospholipase A1 (Ves v1), hyaluronidase (Ves v2) and antigen 5 (Ves v5)...
July 21, 2017: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/28675375/specific-immunotherapy-in-hymenoptera-venom-allergy-and-concomitant-malignancies-a-retrospective-follow-up-focusing-on-efficacy-and-safety
#15
J Aeberhard, G Haeberli, U R Müller, A Helbling
BACKGROUND: Malignancies are often considered as a contraindication for allergen specific immunotherapy. This aspect must be discussed in regards to the population with severe Hymenoptera venom allergy and cancer. The aim of this retrospective study was to conduct a further examination of patients with Hymenoptera venom allergy, venom immunotherapy (VIT) and a malignancy. Methodology: All patients have been included who were referred for evaluation of a Hymenoptera venom allergy or for control during VIT from January 1, 2004 to December 31, 2008...
July 4, 2017: Journal of Investigational Allergology & Clinical Immunology
https://www.readbyqxmd.com/read/28638279/preventive-actions-of-allergen-immunotherapy-the-facts-and-the-effects-in-search-of-evidence
#16
REVIEW
Irene Martignago, Cristoforo Incorvaia, Erminia Ridolo
Allergen immunotherapy (AIT) is the only treatment that works on the causes of allergy. Available AIT nowadays are subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) for allergic rhinitis and asthma, while for allergy to Hymenoptera venom only subcutaneous route is recommended. A bulk of trials and meta-analyses demonstrated that efficacy and safety of AIT in decreasing allergic clinical symptoms and use of rescue medications, while its preventive capacity is yet under investigation. The most important of these effects is the prevention of potentially fatal anaphylactic reactions to Hymenoptera stings by venom immunotherapy (VIT)...
2017: Clinical and Molecular Allergy: CMA
https://www.readbyqxmd.com/read/28604163/allergen-specific-immunotherapy-of-hymenoptera-venom-allergy-also-a-matter-of-diagnosis
#17
Maximilian Schiener, Anke Graessel, Markus Ollert, Carsten B Schmidt-Weber, Simon Blank
Stings of hymenoptera can induce IgE-mediated hypersensitivity reactions in venom-allergic patients, ranging from local up to severe systemic reactions and even fatal anaphylaxis. Allergic patients' quality of life can be mainly improved by altering their immune response to tolerate the venoms by injecting increasing venom doses over years. This venom-specific immunotherapy is highly effective and well tolerated. However, component-resolved information about the venoms has increased in the last years. This knowledge is not only able to improve diagnostics as basis for an accurate therapy, but was additionally used to create tools which enable the analysis of therapeutic venom extracts on a molecular level...
October 3, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28507496/safety-and-efficacy-of-venom-immunotherapy-a-real-life-study
#18
Agnieszka Kołaczek, Dawid Skorupa, Monika Antczak-Marczak, Piotr Kuna, Maciej Kupczyk
INTRODUCTION: Venom immunotherapy (VIT) is recommended as the first-line treatment for patients allergic to Hymenoptera venom. AIM: To analyze the safety and efficacy of VIT in a real life setting. MATERIAL AND METHODS: One hundred and eighty patients undergoing VIT were studied to evaluate the safety, efficacy, incidence and nature of symptoms after field stings and adverse reactions to VIT. RESULTS: Significantly more patients were allergic to wasp than bee venom (146 vs...
April 2017: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/28503403/diagnostics-in-hymenoptera-venom-allergy-current-concepts-and-developments-with-special-focus-on-molecular-allergy-diagnostics
#19
Thilo Jakob, David Rafei-Shamsabadi, Edzard Spillner, Sabine Müller
BACKGROUND: The high rate of asymptomatic sensitization to Hymenoptera venom, difficulty in correctly identifying Hymenoptera and loss of sensitization over time make an accurate diagnosis of Hymenoptera venom allergy challenging. Although routine diagnostic tests encompassing skin tests and the detection of venom-specific IgE antibodies with whole venom preparations are reliable, they offer insufficient precision in the case of double sensitized patients or in those with a history of sting anaphylaxis, in whom sensitization cannot be proven or only to the presumably wrong venom...
2017: Allergo Journal International
https://www.readbyqxmd.com/read/28501976/component-resolved-diagnosis-in-hymenoptera-anaphylaxis
#20
REVIEW
D Tomsitz, K Brockow
PURPOSE OF REVIEW: Hymenoptera anaphylaxis is one of the leading causes of severe allergic reactions and can be fatal. Venom-specific immunotherapy (VIT) can prevent a life-threatening reaction; however, confirmation of an allergy to a Hymenoptera venom is a prerequisite before starting such a treatment. Component resolved diagnostics (CRD) have helped to better identify the responsible allergen. RECENT FINDINGS: Many new insect venom allergens have been identified within the last few years...
June 2017: Current Allergy and Asthma Reports
keyword
keyword
38359
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"